Skip to main content

Table 3 Multiple Cox regression analyses for progression-free and overall survival, both for the proportion of explained variations of clinicopathologic parameters and FAK as well as pFAK for late stage serous ovarian cancer patients (n = 172)

From: Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

A. Overall survival
  Univariate, n = 172 Multiple, n = 140
Characteristics HR (CI 95%) p HR (CI 95%) p
Age (per decade) 1.48 (1.22-1.79) <0.001 1.35 (1.08-1.69) 0.010
FIGO (IV vs III) 2.48 (1.51-4.06) <0.001 3.35 (1.84-6.09) <0.001
Grade (3 vs 1,2) 1.56 (0.91-2.68) 0.105 1.64 (0.83-3.24) 0.155
Residual tumor (yes vs no) 1.77 (1.12-2.78) 0.014 1.33 (0.78-2.24) 0.292
Peritoneal carcinomatosis (yes vs no) 3.11 (1.64-5.90) <0.001 3.18 (1.43-7.11) 0.005
Yoshihara subclassification (subclass 2 vs 1) 2.51 (1.49-4.24)* 0.001 2.23 (1.29-3.87) 0.004
FAK (high vs low) 0.85 (0.41-1.77) 0.671 0.91 (0.37-2.24) 0.830
pFAK (high vs low) 0.80 (0.50-1.27) 0.343 0.54 (0.31-0.96) 0.034
B. Progression free survival
  Univariate, n = 172 Multiple, n = 140
Characteristics HR (CI 95%) p HR (CI 95%) p
Age (per decade) 1.25 (1.08-1.44) 0.003 1.19 (1.01-1.41) 0.042
FIGO (IV vs III) 2.81 (1.83-4.31) <0.001 3.04 (1.83-5.06) <0.001
Grade (3 vs 1,2) 1.32 (0.89-1.97) 0.171 1.01 (0.61-1.66) 0.971
Residual tumor (yes vs no) 1.94 (1.35-2.81) <0.001 1.40 (0.91-2.17) 0.127
Peritoneal carcinomatosis (yes vs no) 2.77 (1.78-4.32) <0.001 3.13 (1.80-5.46) <0.001
Yoshihara subclassification (subclass 2 vs 1) 1.61 (1.09-2.36)** 0.016 1.36 (0.90-2.04) 0.142
FAK (high vs low) 0.87 (0.48-1.58) 0.654 0.89 (0.41-1.95) 0.776
pFAK (high vs low) 1.15 (0.81-1.63) 0.425 1.02 (0.66-1.57) 0.927
  1. P-values and adjusted p-values below 0.05 are shown in bold. *n = 141 (due to the limited availability of microarray data).